1-(5'-chloro-3-methyl-2,4'-bipyridin-2'-yl)-N-[2-(2-oxo-2,3-dihydro-1H-indol-3-yl)ethyl]piperidine-4-carboxamide | 1373614-73-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-(5'-chloro-3-methyl-2,4'-bipyridin-2'-yl)-N-[2-(2-oxo-2,3-dihydro-1H-indol-3-yl)ethyl]piperidine-4-carboxamide
• 英文别名: 1-[5-chloro-4-(3-methylpyridin-2-yl)pyridin-2-yl]-N-[2-(2-oxo-1,3-dihydroindol-3-yl)ethyl]piperidine-4-carboxamide
• CAS: 1373614-73-3
• 化学式: C₂₇H₂₈ClN₅O₂
• 分子量: 490.005
• InChiKey: CLPWZBZTSOALRY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  87.2
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] PYRIDINE- 2- DERIVATIVES AS SMOOTHENED RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS DE PYRIDINE-2 EN TANT QUE MODULATEURS DES RÉCEPTEURS SMOOTHENED
  申请人：PFIZER

  公开号：WO2012052948A1

  公开（公告）日：2012-04-26

  The present application relates to compounds of Formula (I), and Formula (II), or pharmaceutically acceptable salt thereof, wherein A, X, Y, Z, e, f, R1, R2, R3, R4, R5, R5b, R6, R7, R8, R9, R10, R11,R20, R21, R22 and R23 are defined herein. These novel pyridine derivatives that are useful in therapy, in particular for treating diseases or conditions mediated by Smo, including the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to methods of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.

  本申请涉及式(I)和式(II)化合物，或其药用盐，其中A、X、Y、Z、e、f、R1、R2、R3、R4、R5、R5b、R6、R7、R8、R9、R10、R11、R20、R21、R22和R23在此处有定义。这些新型吡啶衍生物在治疗中很有用，特别是用于治疗由Smo介导的疾病或症状，包括治疗哺乳动物中的异常细胞生长，如癌症。另外，还涉及使用这些化合物治疗哺乳动物中的异常细胞生长的方法，特别是人类，并且涉及含有这些化合物的药物组合物。
• PYRIDINE-2-DERIVATIVES AS SMOOTHENED RECEPTOR MODULATORS
  申请人：Nair Sajiv Krishnan

  公开号：US20130210800A1

  公开（公告）日：2013-08-15

  The present application relates to compounds of Formula (I), and Formula (II), or pharmaceutically acceptable salt thereof, wherein A, X, Y, Z, e, f, R 1 , R 2 , R 3 , R 4 , R 5 , R 5b , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 20 , R 21 , R 22 and R 23 are defined herein. These novel pyridine derivatives that are useful in therapy, in particular for treating diseases or conditions mediated by Smo, including the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to methods of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.

  本申请涉及式(I)和式(II)的化合物，或其药学上可接受的盐，其中A、X、Y、Z、e、f、R1、R2、R3、R4、R5、R5b、R6、R7、R8、R9、R10、R11、R20、R21、R22和R23在此被定义。这些新型吡啶衍生物在治疗中有用，特别是用于治疗由Smo介导的疾病或病况，包括治疗哺乳动物中的异常细胞生长，如癌症。其他实施例涉及使用这些化合物治疗哺乳动物，特别是人类中的异常细胞生长的方法，以及包含这些化合物的制药组合物。
• PYRIDINE- 2- DERIVATIVES AS SMOOTHENED RECEPTOR MODULATORS
  申请人：Pfizer Inc.

  公开号：EP2630134A1

  公开（公告）日：2013-08-28
• PYRIDINE-2- DERIVATIVES AS SMOOTHENED RECEPTOR MODULATORS
  申请人：Pfizer Inc.

  公开号：EP2630134B1

  公开（公告）日：2015-05-20
• US9056865B2
  申请人：——

  公开号：US9056865B2

  公开（公告）日：2015-06-16